Manish A. Shah, MD, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Manish A. Shah, MD, director of Gastrointestinal Oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Overall, the results were disappointing, Shah says. While andecaliximab demonstrated an improved overall response rate, there was no improvement in progression-free survival or overall survival in the unselected patient population. However, patients over the age of 65 seemed to have benefit.
Investigators conducted a sensitivity analysis and split the groups according to age to see if there was a step-wise increased benefit with the youngest group to the oldest. Shah says there was, suggesting there may be a signal here. More work must be done in order to find factors that may lead to this specific sensitivity in the older patient population, Shah concludes.
See more from the 2019 Gastrointestinal Cancers Symposium.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More